Nevertheless, CD133-targeted therapy against LCSCs by genetically engineered immune cells could potentially serve as an alternative treatment strategy for late-stage HCC patients who are refractory to the currently available treatment options. This evidence concerns the gene PROM1 and hepatocellular carcinoma.